HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Genetic Variability of Hepatitis C Virus (HCV) 5' Untranslated Region in HIV/HCV Coinfected Patients Treated with Pegylated Interferon and Ribavirin.

Abstract
Association between hepatitis C virus (HCV) quasispecies and treatment outcome among patients with chronic hepatitis C has been the subject of many studies. However, these studies focused mainly on viral variable regions (E1 and E2) and usually did not include human immunodeficiency virus (HIV)-positive patients. The aim of the present study was to analyze heterogeneity of the 5' untranslated region (5'UTR) in HCV/HIV coinfected patients treated with interferon and ribavirin. The HCV 5'UTR was amplified from serum and peripheral blood mononuclear cells (PBMC) samples in 37 HCV/HIV coinfected patients treated for chronic hepatitis C. Samples were collected right before treatment, and at 2, 4, 6, 8, 12, 20, 24, 36, 44, 48, 60, and 72 weeks. Heterogeneity of the 5'UTR was analyzed by single strand conformational polymorphism (SSCP), cloning and sequencing. Sustained virological response (SVR) was achieved in 46% of analyzed HCV/HIV co-infected patients. Stable SSCP band pattern was observed in 22 patients (62.9%) and SVR rate among these patients was 23%. Decline in the number of bands and/or shift in band positions were found in 6 patients (17.1%), 5 (83%) of whom achieved SVR (p=0.009). A novel viral genotype was identified in all but one of these patients. In 5 of these 6 patients a new genotype was dominant. 5'UTR heterogeneity may correlate with interferon and ribavirin treatment outcome. In the analyzed group of HCV/HIV coinfected patients, viral quasispecies stability during treatment favored viral persistence, whereas decrease in the number of variants and/or emergence of new variants was associated with SVR. Among injection drug users (IDU) patients, a new genotype may become dominant during treatment, probably due to the presence of mixed infections with various strains, which have different susceptibility to treatment.
AuthorsIwona Bukowska-Ośko, Agnieszka Pawełczyk, Karol Perlejewski, Natalia Kubisa, Kamila Caraballo Cortés, Magdalena Rosińska, Rafał Płoski, Maria Fic, Justyna Kaźmierczak, Marta Popiel, Piotr Ząbek, Andrzej Horban, Marek Radkowski, Tomasz Laskus
JournalPloS one (PLoS One) Vol. 10 Issue 5 Pg. e0125604 ( 2015) ISSN: 1932-6203 [Electronic] United States
PMID25932941 (Publication Type: Journal Article)
Chemical References
  • 5' Untranslated Regions
  • Antiviral Agents
  • Interferon-alpha
  • Interleukins
  • Ribavirin
Topics
  • 5' Untranslated Regions (genetics)
  • Adult
  • Antiviral Agents (pharmacology, therapeutic use)
  • Base Sequence
  • Coinfection (drug therapy, virology)
  • Female
  • Genetic Variation
  • HIV (drug effects, genetics)
  • Hepacivirus (drug effects, genetics)
  • Humans
  • Interferon-alpha (pharmacology, therapeutic use)
  • Interleukins (genetics)
  • Male
  • Middle Aged
  • Molecular Sequence Data
  • Polymorphism, Single-Stranded Conformational (genetics)
  • Ribavirin (pharmacology, therapeutic use)
  • Sequence Alignment
  • Treatment Outcome
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: